Clinical Trials Browser

Phase 2 × Esophageal Neoplasms × regorafenib × Clear all

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT01913639 2020-05-15

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Phase 2 Completed

39 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms